Candel Therapeutics (CADL) EBITDA Margin (2020 - 2022)
Candel Therapeutics (CADL) posted EBITDA Margin of 26132.26% for Q4 2022, up 8.78% sequentially from 28648.39% in Q3 2022, and up 10286774.0% YoY from N/an in Q4 2021.
Candel Therapeutics (CADL) EBITDA Margin (2020 - 2022) Analysis & Trends
Candel Therapeutics has reported EBITDA Margin for 3 years, with the latest figure at 26132.26% in Q4 2022.
- Quarterly EBITDA Margin rose 10286774.0% year-over-year to 26132.26% in Q4 2022, while the trailing twelve-month figure through Dec 2022 was 28000.81% (down 201394.0% YoY) and the FY2022 annual result came in at 27777.6%, down 205160.0% from the prior year.
- EBITDA Margin climbed to 26132.26% in Q4 2022 per CADL's latest filing, from 28648.39% in the prior quarter.
- Over five years, EBITDA Margin peaked at 8448.39% in Q2 2020 and troughed at 129000.0% in Q4 2021.
- A 3-year average of 30554.55% and a median of 25900.0% in 2021 frame the typical range for EBITDA Margin.
- The sharpest annual moves came in 2021 and 2022: EBITDA Margin sank 10924194 bps in 2021, then soared 10286774 bps in 2022.
- Over 3 years, EBITDA Margin stood at 19758.06% in 2020, then sank by 553 bps to 129000.0% in 2021, then soared by 80 bps to 26132.26% in 2022.
- According to Business Quant data, EBITDA Margin over the past three periods registered 26132.26%, 28648.39%, and 28235.48% for Q4 2022, Q3 2022, and Q2 2022 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 31.68% |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 19.06% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -77,569,866.34% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.75% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 17.93% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -0.36% |
| 10 | Candel Therapeutics | 643.41 Mn | 643.41 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2022 | -26,132.26% |
| Sep 30, 2022 | -28,648.39% |
| Jun 30, 2022 | -28,235.48% |
| Mar 31, 2022 | -28,987.10% |
| Dec 31, 2021 | -129,000.00% |
| Sep 30, 2021 | -25,900.00% |
| Jun 30, 2021 | -17,100.00% |
| Mar 31, 2021 | -15,022.58% |
| Dec 31, 2020 | -19,758.06% |
| Sep 30, 2020 | -8,867.74% |
| Jun 30, 2020 | -8,448.39% |